MODIFICATION
65 -- Production of blocking Rabbit Monoclonal Antibody against human CD97.
- Notice Date
- 8/31/2016
- Notice Type
- Modification/Amendment
- NAICS
- 325413
— In-Vitro Diagnostic Substance Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC62562-61
- Archive Date
- 9/21/2016
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov
(ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E1644, Bethesda, MD 20852, UNITED STATES. Description The National Cancer Institute (NCI), Cancer Center Research (CCR), The Laboratory of Genitourinary Cancer Pathogenesis (LGCP) plans to procure on a sole source basis for 0a custom rabbit monoclonal blocking antibody directed against human CD97 manufactured by Abcam Burlingame, 863 Mitten Road, Suite 103-104, Burlingame, CA 94010-1303. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1). Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The North American Industry Classification System code is 325414 and the business size standard is 1250. Period of performance shall be for twelve (12) months from date of award. It has been determined that there is no opportunity to acquire green products or services under this contract. The Purpose of this acquisition is to procure Production of blocking Rabbit Monoclonal Antibody against human CD97. The human CD97, a G protein-coupled receptor, is absent in normal epithelial cells but increases in expression in parallel with malignant grade in several carcinomas. Current investigative efforts toward understanding the role of CD97 in cancer biology has been hindered by the lack of a reliable CD97 blocking antibody. A blocking antibody does not have a reaction when combined with an antigen, but prevents other antibodies from combining with that antigen. Screening of current commercially available CD97 antibody sources has unfortunately failed to uncover any polyclonal or monoclonal antibodies able to block CD97 binding. Therefore, the LGCP has a need to produce a rabbit monoclonal CD97 blocking antibody to further our investigative efforts, and provide a useful tool for the CD97 research field. Antibodies from rabbits are generally of higher affinity than those from mice. Results obtained from the contractor and other researchers indicate that the binding affinity of rabbit monoclonal antibodies is on average 100 times higher, offering better sensitivity and specificity in biological assays. Rabbit monoclonal antibodies recognize many antigens that are not immunogenic in mice, including small molecule haptens, some cell surface epitopes, modified sites (e.g., phosphorylation, acetylation, methylation, glycosylation, etc.) and most rodent proteins. The rabbit system offers 40 times as many lymphocytes compared to mouse and the 240E cell line used for fusion is much more robust than any of the mouse cell lines used for fusion. Because of the large size of the rabbit spleen, more fusion experiments can be performed, making hybridoma generation at industrial scale a feasible task. The contractor shall generate up to 9 hybridoma subclones from as many as 3 parent hybridoma cell lines chosen by NCI/LGCP as a result of screening. The production required to blocking Rabbit Monoclonal Antibody possesses the following characteristics: Phase I: Rabbit Polyclonal Antibody Service - Immunization of two (2) rabbits using standard immunization of five (5) injections and collection of one (1) pre-bleed and two (2) test bleeds per rabbit. - Monitor antiserum titer using standard ELISA. - Counter-screen with Fc fusion protein. - Discuss titer results with NCI to select rabbit for splenectomy. - Final IV and splenectomy (Final IV must be scheduled within 4-8 weeks of last regular injection boost). Phase IIa: Rabbit Monoclonal Antibody Service - Isolate all the lymphocytes from one rabbit spleen. - Store all remaining lymphocytes in liquid nitrogen for up to three (3) months after the termination of the project. Phase IIb: Rabbit Monoclonal Antibody Service - Perform hybridoma fusion of 80 x 96-well plates. - Perform standard ELISA screening of 80 x 96-well plates. - Expand all positive hybridomas to 24-well plates and perform confirming standard ELISA. - Counter-screen with Fc Fusion Protein. - Transfer and deliver all standard ELISA positive multi-clone supernatants (1 ml each) for a two week screening by NCI. Phase IIIa: Rabbit Monoclonal Antibody Service - Subclone up to 3 multclone hybridomas chosen by NCI. - Perform standard ELISA screening of supernatants. - For each hybridoma chosen, deliver supernatants (1 ml each) from subclones for a two week screening by NCI. - Freezing and storage of backup (3) multiclone hybridomas. Phase IIIb: Rabbit Monoclonal Antibody Service - Expand up to nine (9) final hybridoma subclones from each parental clone as frozen cells. - Store subclones for three (3) months following project completion. Phase IIIc: Rabbit Monoclonal Antibody Service - Culture one (1) hybridoma subclone (1L). - Perform two (2) hybridoma supernatant harvest collections. - Perform standard ELISA screening and spectroscopic concentration determination of supernatant. - Purify the hybridoma supernatant using a Protein A column. - Analyze the purify sample via gel electrophoresis, spectroscopic concentration determination, and ELISA. QUESTIONS ARE DUE: September 2, 2016 This is not a solicitation for competitive quotations. However, if any interested parties, especially small businesses, believe they can meet the above requirement, they may submit a statement of capabilities. All information furnished must be in writing and must contain sufficient detail to allow the NCI to determine if it can meet the above unique specifications described herein. A copy of the capability statement must be received in the NCI Office of Acquisition on or before 11:00 AM EST on September 6, 2016. All questions must be in writing and can be faxed (240) 276-5401 or emailed to Kathy Elliott, Contract Specialist at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, contractors must have valid registration and certification on Sam.gov, www.sam.gov. No collect calls will be accepted. Please reference solicitation number N02RC62562-61 all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC62562-61/listing.html)
- Place of Performance
- Address: 9000 Rockville Pike, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN04248642-W 20160902/160831235155-514c4ba886b0f6778594a32ad13a96c2 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |